Report Overview

China Pompe Disease Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Pompe diseaseis a rare inherited and often fataldisorderthat disables the heart and skeletal muscles. It is caused by mutations in a gene that makes an enzyme called acid alpha-glucosidase (GAA). Incidence of Pompe disease in China is 1:50,000 population, there are about 35000 (80% adults and 20% babies) Pompe patients in China. It occurs equally in males and females but varies depending on race and geographic location.



Market Drivers

China is a growing market for Pompe disease due to factors such as increased research in the field ofpompe diseaseis set to propel the growth of themarket. Increasing developments in the gene therapy and enzyme replacement therapies aredrivingfactors for the growth ofPompe disease market. In addition to these increase in Chinas incidence rate (1:50,000 population), prevalence rate and increase in R&D activities contributes to the growth of the Pompe disease market in China.

However, there are some restraining factors for the growth of Pompe disease therapeutics market in China such as high cost of treatment and complex diagnosis process.